Short answer
There is no convincing scientific evidence that secukinumab (Cosentyx®) directly impairs fertility or other aspects of a woman’s reproductive function. However, because it is a biologic immunomodulator and the pregnancy data are sparse, the drug is labeled contraindicated in pregnancy, and women of child‑bearing potential are advised to use reliable contraception and to discuss family‑planning plans with their prescribing clinician.
---
What the science actually says
| Question | What we know | What we don’t know |
|----------|--------------|-------------------|
| Does secukinumab affect fertility? | Human studies – No controlled trials have examined fertility outcomes in women taking secukinumab. | Direct evidence – There are no randomized trials or large observational studies that specifically look at conception rates, time to pregnancy, or ovarian function in women who have taken the drug. |
| Does it harm a developing fetus? | Animal studies – In rats and rabbits, high‑dose secukinumab did not show teratogenicity or reproductive toxicity, but the relevance to humans is limited. | Human data – Very few pregnancies have been reported in women who were exposed to secukinumab (mostly post‑marketing reports). Those case reports show a mix of outcomes but are far from definitive. |
| What does the prescribing information say? | Secukinumab is contraindicated in pregnancy because of the lack of data. The label recommends that women who are pregnant or planning to become pregnant discontinue therapy. | Wash‑out period – The label does not provide a specific discontinuation interval, but due to secukinumab’s long half‑life (~27 days), the drug can stay in the system for several months. |
| Does it affect breastfeeding? | Human data – Very limited. A few case reports suggest that secukinumab is excreted into breast milk in trace amounts, but the clinical significance is unknown. | Guideline consensus – Many professional societies recommend against breastfeeding while on secukinumab. |
| What about contraception? | Clinical practice – Women of child‑bearing potential should use effective contraception (e.g., combined oral contraceptives, copper IUD, barrier methods, or hormonal implants). | Effectiveness data – No studies have examined the impact of secukinumab on contraceptive efficacy. |
---
Practical guidance
1. Talk to your clinician before conceiving.
- Discuss the risks of continuing secukinumab, potential alternatives, and an individualized plan for pregnancy planning.
2. Consider a wash‑out period.
- Because secukinumab’s half‑life is long, most clinicians recommend stopping therapy at least 4–6 weeks before attempting conception, but this may vary based on disease severity and clinical judgment.
3. Use reliable contraception.
- While on secukinumab, use dual methods (e.g., hormonal plus barrier) if you wish to avoid pregnancy.
4. If you become pregnant while on secukinumab
- Contact your dermatologist or rheumatologist promptly. Current data are limited, but most clinicians would advise discontinuing the drug and closely monitoring both maternal disease activity and fetal development.
5. Pregnancy after stopping secukinumab
- No known long‑term reproductive harm has been documented in the limited data available, but ongoing research may change recommendations in the future.
---
Bottom line
- No robust evidence suggests secukinumab directly harms fertility or causes infertility in women.
- Limited human pregnancy data and the drug’s immunologic mechanism lead to a label contraindication in pregnancy.
- Clinical best practice is to avoid pregnancy while taking secukinumab, use effective contraception, and discuss family‑planning strategies with your healthcare provider.
If you have specific concerns about fertility or pregnancy, it’s best to consult a specialist—such as a dermatologist, rheumatologist, or reproductive endocrinologist—who can tailor advice to your individual health status and treatment plan.